| __timestamp | Blueprint Medicines Corporation | HUTCHMED (China) Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 7890000 | 26684000 |
| Thursday, January 1, 2015 | 14456000 | 29829000 |
| Friday, January 1, 2016 | 19218000 | 39578000 |
| Sunday, January 1, 2017 | 27986000 | 43277000 |
| Monday, January 1, 2018 | 47928000 | 48645000 |
| Tuesday, January 1, 2019 | 96388000 | 52934000 |
| Wednesday, January 1, 2020 | 157743000 | 61349000 |
| Friday, January 1, 2021 | 195293000 | 127125000 |
| Saturday, January 1, 2022 | 237374000 | 136106000 |
| Sunday, January 1, 2023 | 295141000 | 133175999 |
| Monday, January 1, 2024 | 359272000 |
Data in motion
In the dynamic world of biotechnology, understanding financial trends is crucial for investors and stakeholders. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent companies: Blueprint Medicines Corporation and HUTCHMED (China) Limited, from 2014 to 2023.
Blueprint Medicines has shown a remarkable increase in SG&A expenses, growing nearly 3,700% over the decade. This surge reflects their aggressive expansion and investment in marketing and administrative capabilities. In contrast, HUTCHMED's expenses have increased by approximately 400%, indicating a more conservative growth strategy.
By 2023, Blueprint Medicines' SG&A expenses reached nearly double those of HUTCHMED, highlighting their commitment to scaling operations. This trend suggests a strategic focus on capturing market share and enhancing operational infrastructure. Investors should consider these financial trajectories when evaluating the companies' long-term growth potential and market positioning.
Breaking Down SG&A Expenses: Ascendis Pharma A/S vs Blueprint Medicines Corporation
Breaking Down SG&A Expenses: Blueprint Medicines Corporation vs ACADIA Pharmaceuticals Inc.
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and Agios Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and Celldex Therapeutics, Inc.
CRISPR Therapeutics AG or HUTCHMED (China) Limited: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Veracyte, Inc. and HUTCHMED (China) Limited
Selling, General, and Administrative Costs: MorphoSys AG vs HUTCHMED (China) Limited
Operational Costs Compared: SG&A Analysis of Catalyst Pharmaceuticals, Inc. and HUTCHMED (China) Limited
HUTCHMED (China) Limited vs ImmunityBio, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: HUTCHMED (China) Limited vs Amphastar Pharmaceuticals, Inc. Trends and Insights
HUTCHMED (China) Limited or Travere Therapeutics, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of HUTCHMED (China) Limited and Viridian Therapeutics, Inc.